Collectively, our results indicate a new function of PAFR-agonists as molecules that can fine tune not only innate, but adaptive responses as well, suggesting a potential application of PAFR antagonists in DCs-based vaccination protocols for cancer and other diseases, or the use of a PAFR antagonist as an adjuvant in immunization protocols. Here, PTAFR is linked to cancer.